Published online Dec 26, 2020. doi: 10.4330/wjc.v12.i12.615
Peer-review started: June 18, 2020
First decision: September 18, 2020
Revised: October 15, 2020
Accepted: November 5, 2020
Article in press: November 5, 2020
Published online: December 26, 2020
Processing time: 182 Days and 0.9 Hours
Core Tip: New-generation drug-eluting stents (DES) reduce the risk of stent thrombosis. However, the everolimus-eluting coronary stent system (EES) exerts higher interaction with rapamycin complex 2, higher bioavailability, shorter half-life than sirolimus, decreases vascular inflammation and promotes rapid endothelialization; therefore, outperforms paclitaxel DES in safety and efficacy. EverProTM, a second-generation EES with a biodegradable polymer and a 60 μm cobalt-chromium platform design, facilitates reduction in intra-arterial injury. This observational study enrolled 77 patients with coronary artery disease (CAD), implanted with the EverProTM stent who completed a 1-year follow-up period after the index procedure. Our findings suggested that EverProTM EES is safe and effective with no major adverse cardiac events/stent thrombosis during the 1 year follow-up period in patients with CAD.